Myelofibrosis Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – Estimates DelveInsight | AbbVie, Roche, Celgene, Cellenkos, Galecto, Geron, Incyte, Karyopharm

Myelofibrosis Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) -  Estimates DelveInsight | AbbVie, Roche, Celgene, Cellenkos, Galecto, Geron, Incyte, Karyopharm
Delveinsight Business Research LLP
The Myelofibrosis market size in the seven major markets is expected to increase during the study period (2019–2032) with a CAGR of 7.3%. As per DelveInsight, the Myelofibrosis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Myelofibrosis, extensive research and development activities of pharmaceutical companies, and the expected launch of approved therapies.

DelveInsight’s “Myelofibrosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Myelofibrosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Myelofibrosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Myelofibrosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Myelofibrosis: An Overview

Myelofibrosis (MF) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibers on which the stem cells can divide and grow. Specialized cells in the bone marrow known as fibroblasts make these fibers.

Mutations in the JAK2, MPL, CALR, and TET2 genes are associated with most cases of primary myelofibrosis. Primary myelofibrosis is most commonly diagnosed in people aged 50 to 80 but can occur at any age. Myelofibrosis can also progress to other, more aggressive, types of more aggressive forms.

Patients who are symptom-free and do not have signs of anemia, an enlarged spleen, or other complications are generally not treated. Some people remain stable and symptom-free for many years. However, these patients need to be monitored closely through regular medical checkups and examinations to detect any signs and symptoms of disease progression.

The treatment goal for most patients with myelofibrosis is to relieve symptoms, reduce an enlarged spleen, improve blood cell counts (i.e., anemia), and reduce the risk of complications. Many key players like GSK, AbbVie, Incyte, Celgene/BMS, MorphoSys, and others are engaged in developing therapies to address these unmet needs of patients.

Myelofibrosis Market Key Facts

  • According to the estimates, the highest market size of Myelofibrosis is found in the United States, followed by Japan.

  • The total Myelofibrosis market size of therapies in the United States is expected to increase with a CAGR of 8.0% in the study period (2019–2032).

  • The total Myelofibrosis market size of therapies in EU-5 countries is expected to increase with a CAGR of 5.0% in the study period (2019–2032).

  • The total prevalent population of myelofibrosis in the 7MM comprised of 39,735 cases in 2021 and is projected to increase during the study period (2019–2032).

  • In the United States, the total number of prevalent cases of Myelofibrosis was 19,815 cases in the year 2021.

  • Among the EU-5 countries, Germany accounted for the highest number of myelofibrosis diagnosed prevalent cases, followed by the UK, whereas Spain accounted for the lowest number of cases in 2021.

  • The total number of diagnosed prevalent cases of myelofibrosis in Japan is 5,391 in 2021.

Myelofibrosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Myelofibrosis pipeline therapies. It also thoroughly assesses the Myelofibrosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Myelofibrosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Myelofibrosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Myelofibrosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Myelofibrosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Myelofibrosis Epidemiology, Segmented as –

  • Total Prevalent Cases of Myelofibrosis in the 7MM (2019–2032)

  • Myelofibrosis Cases Based on Molecular Alterations in the 7MM (2019–2032)

  • Age-specific Prevalent Cases of Myelofibrosis in the 7MM (2019–2032)

  • Myelofibrosis Cases Based on Risk Stratification in the 7MM (2019–2032)

  • Total Diagnosed Prevalent cases of Myelofibrosis in the 7MM (2019–2032)

  • Type-specific Prevalent Cases of Myelofibrosis in the 7MM (2019–2032)

Myelofibrosis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Myelofibrosis market or expected to be launched during the study period. The analysis covers the Myelofibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Myelofibrosis drugs based on their sale and market share.

The report also covers the Myelofibrosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Myelofibrosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Myelofibrosis Market Will Evolve and Grow by 2032 @

Myelofibrosis Therapeutics Analysis

No drug therapy can cure myelofibrosis. The only potential cure for myelofibrosis is allogeneic stem cell transplantation, but this procedure is risky for older patients and those with other health problems. As myelofibrosis primarily affects older adults, stem cell transplantation is not a treatment option for most myelofibrosis patients. For most people with myelofibrosis, treatment remains aimed at controlling disease symptoms and complications, enhancing the quality of life, and extending survival.

Current marketed drugs include ruxolitinib (JAKAFI), fedracitinib (INREBIC), pacritinib (VONJO). The emerging pipeline is full of late stage drugs including key players like Incyte corporation, Geron Corporation, AbbVie, BMS, etc. which are testing their candidates in this rare indication.

Several major pharma and biotech companies are developing therapies for Myelofibrosis. Currently, Incyte Corporation is leading the therapeutics market with its Myelofibrosis drug candidates in the most advanced stage of clinical development. Coming therapies are focusing on different mechanisms other than JAK inhibitors, such as imetelstat (telomerase inhibitor), navitoclax (BCL-XL/BCL-2 inhibitor), GB2064 (LOXL2 protein inhibitors), navtemadlin (MDM2 protein inhibitor), pelabresib (BET inhibitor), and others which may cover the patient need in refractory and relapse to JAK inhibitor and provide an alternative treatment for the patients.

Myelofibrosis Companies Actively Working in the Therapeutics Market Include

AbbVie, Actuate Therapeutics, AstraZeneca, Bristol Myers Squibb, Celgene Corporation, Cellenkos, Galecto Biotech, Geron Corporation, Imago BioSciences, Incyte Corporation, Jacobio Pharmaceuticals, Kartos Therapeutics, Karyopharm Therapeutics, Keros Therapeutics, Menarini Group, MorphoSys, Novartis Oncology, NS Pharma, Ohm oncology, PharmaEssentia, Pharmaxis, Roche, Secura Bio, Sierra Oncology, Telios Pharma, and many others.

Emerging and Marketed Myelofibrosis Therapies Covered in the Report Include:

  • Parsaclisib: Incyte Corporation

  • KER-050: Keros Therapeutics

  • JAKAFI (Ruxolitinib): Incyte/Novartis

  • INREBIC (Fedratinib): Impact Biomedicines/Celgene

  • VONJO (Pacritinib): CTI BioPharma

  • Momelotinib: Sierra Oncology

  • Navitoclax (ABT-263): AbbVie

  • Parsaclisib (INCB050465): Incyte

  • REBLOZYL (Luspatercept/ACE-536): Celgene/Bristol Myers Squibb

  • Pelabresib: MorphoSys

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Myelofibrosis Competitive Intelligence Analysis

4. Myelofibrosis Market Overview at a Glance

5. Myelofibrosis Disease Background and Overview

6. Myelofibrosis Patient Journey

7. Myelofibrosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Myelofibrosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Myelofibrosis Unmet Needs

10. Key Endpoints of Myelofibrosis Treatment

11. Myelofibrosis Marketed Therapies

12. Myelofibrosis Emerging Drugs and Latest Therapeutic Advances

13. Myelofibrosis Seven Major Market Analysis

14. Attribute Analysis

15. Myelofibrosis Market Outlook (In US, EU5, and Japan)

16. Myelofibrosis Companies Active in the Market

17. Myelofibrosis Access and Reimbursement Overview

18. KOL Views on the Myelofibrosis Market

19. Myelofibrosis Market Drivers

20. Myelofibrosis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Intracardiac Echocardiography Devices Market

The global intracardiac echocardiography devices market is estimated to grow at a CAGR of 5.33% during the forecast period from 2023 to 2028. The demand for intracardiac echocardiography devices is primarily being boosted by the increasing prevalence of arrhythmia, atrial septal defects, and other cardiovascular diseases. Further, the rising figures of elderly patients, rising demand for minimally invasive approaches, increasing lifestyle disorders, and technological innovations pertaining to cardiac-related devices, among others. Some of the key market players operating in the intracardiac echocardiography devices market include Stryker, Boston Scientific Corporation, NuVera Medical, Inc., Abbot, Johnson & Johnson Services, Inc., Koninklijke Philips N.V., Stereotaxis Inc., GE Healthcare, and others.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States